NCT01658150View on ClinicalTrials.gov

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 2, 2018

Study Completion Date

January 2, 2018

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

isradipine

Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors
All Listed Sponsors
collaborator

Brain & Behavior Research Foundation

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER